BLACK BOX WARNING
- high potential for abuse and dependence — Schedule II controlled substance; assess for history of drug dependence before prescribing
methylphenidate
Brand: Ritalin, Concerta, Metadate, Quillivant XR, Daytrana
⚠ BBW Prototype Drug
Drug Class: CNS stimulant
Drug Family: CNS stimulant
Subclass: dopamine-norepinephrine reuptake inhibitor
Organ Systems: cns
Mechanism of Action
Blocks reuptake of dopamine and norepinephrine by binding to their respective transporter proteins; increases synaptic monoamine concentrations in prefrontal cortex, improving executive function, attention, and impulse control.
dopamine reuptake transporter (DAT)norepinephrine reuptake transporter (NET)
Indications
- ADHD (children and adults)
- narcolepsy
Contraindications
- concurrent or recent MAOIs
- marked anxiety or agitation
- glaucoma
- tics/Tourette's syndrome (relative)
- known cardiac structural abnormalities
Adverse Effects
Common
- decreased appetite
- insomnia
- headache
- stomach pain
- increased heart rate and blood pressure
- irritability
Serious
- sudden death in patients with structural cardiac abnormalities
- serious cardiovascular events
- new/worsened psychiatric symptoms (mania, psychosis)
- growth suppression in children
- priapism (extended-release formulations, rare)
Pharmacokinetics (ADME)
| Absorption | Well absorbed; IR peak at 1–2 hours; Concerta uses OROS delivery for 12-hour duration |
| Distribution | Protein binding 10–33%; Vd ~2.65 L/kg |
| Metabolism | De-esterification to inactive ritalinic acid; minimal CYP involvement |
| Excretion | Renal (~80%); mostly as ritalinic acid |
| Half-life | 2–3 hours |
| Onset | 30–60 minutes |
| Peak | 1–2 hours (IR); 6–8 hours (ER/Concerta) |
| Duration | 3–5 hours (IR); 8–12 hours (ER) |
| Protein Binding | 10–33% |
| Vd | ~2.65 L/kg |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| MAOIs | hypertensive crisis — 14-day washout required | major |
| clonidine | serious adverse events reported with combination; use with caution | major |
| anticoagulants (warfarin) | methylphenidate may inhibit warfarin metabolism; monitor INR | moderate |
Nursing Considerations
- Monitor height and weight in children every 3–6 months; growth suppression may require drug holidays (weekends/summers) in growing children with significant growth delay
- Obtain baseline cardiovascular evaluation (HR, BP, ECG if indicated); methylphenidate is contraindicated in structural cardiac abnormalities — sudden cardiac death, though rare, is a serious risk
- Administer last dose by early afternoon to minimize insomnia — optimize timing with school/work schedule
- Drug is Schedule II — verify prescription authenticity; assess for diversion; counsel family about secure storage
Clinical Pearls
- Methylphenidate's mechanism is similar to cocaine (DAT/NET blockade) but slower — the abuse potential is partly driven by rate of dopamine increase; slow-release formulations have lower abuse potential than short-acting forms
- Treatment holidays during weekends or summers can help mitigate growth suppression in children but may impair social and academic functioning during those periods — individualize based on severity of ADHD impact
Safety Profile
Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.